Medexus Pharmaceuticals Inc.
MEDXF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $24,741 | $24,615 | $24,754 | $29,992 |
| % Growth | 0.5% | -0.6% | -17.5% | – |
| Cost of Goods Sold | $10,955 | $10,841 | $12,322 | $14,801 |
| Gross Profit | $13,786 | $13,774 | $12,432 | $15,191 |
| % Margin | 55.7% | 56% | 50.2% | 50.7% |
| R&D Expenses | $1,822 | $2,355 | $2,511 | $1,995 |
| G&A Expenses | $8,327 | $8,159 | $8,655 | $6,741 |
| SG&A Expenses | $10,239 | $10,499 | $10,134 | $9,355 |
| Sales & Mktg Exp. | $1,912 | $2,340 | $1,479 | $2,614 |
| Other Operating Expenses | $348 | $70 | $956 | $60 |
| Operating Expenses | $12,409 | $12,924 | $13,601 | $11,410 |
| Operating Income | $1,377 | $850 | -$1,169 | $3,781 |
| % Margin | 5.6% | 3.5% | -4.7% | 12.6% |
| Other Income/Exp. Net | -$1,704 | -$235 | $410 | -$2,901 |
| Pre-Tax Income | -$327 | $615 | -$759 | $880 |
| Tax Expense | -$12 | $99 | -$206 | $147 |
| Net Income | -$315 | $516 | -$553 | $733 |
| % Margin | -1.3% | 2.1% | -2.2% | 2.4% |
| EPS | -0.01 | 0.016 | -0.02 | 0.03 |
| % Growth | -159.3% | 181.4% | -167% | – |
| EPS Diluted | -0.01 | 0.016 | -0.02 | 0.03 |
| Weighted Avg Shares Out | 32,288 | 32,258 | 27,650 | 24,675 |
| Weighted Avg Shares Out Dil | 32,288 | 32,258 | 27,650 | 24,675 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $1,407 | $1,406 | $2,005 | $1,996 |
| Depreciation & Amortization | $2,428 | $2,426 | $2,436 | $1,756 |
| EBITDA | $3,508 | $4,447 | $3,682 | $4,632 |
| % Margin | 14.2% | 18.1% | 14.9% | 15.4% |